Oncopeptides AB (publ) (ONCO.ST)
Oncopeptides AB (publ) operates in the Biotechnology industry of the Healthcare sector, headquartered in Stockholm, AB, SE. The stock last traded at $2.50, up 8.51% on the session, giving a market capitalisation of $604.9M. Its beta of -1.31 implies it has historically moved less than the broad market.
Oncopeptides AB (publ) is a biotechnology firm dedicated to developing medical therapies for cancer, serving markets across the United States, Europe, and worldwide. Its foremost experimental compound, melflufen, is a distinct peptide-drug conjugate engineered to address multiple myeloma that has relapsed or become resistant to prior treatments in adult individuals. Founded in 2000, Oncopeptides AB (publ) conducts its main business from Stockholm, Sweden.
Oncopeptides AB (publ) is most often compared with the following Healthcare names: